In addition to manufacturing, TopoGEN has quietly developed into a CRO powerhouse in recent years. Utilizing our own regimes and expertise that comes with 30+ years of experience, we tailor-build a custom screening solution for your novel anti-cancer studies. Specific targets include eukaryotic topoisomerases (topo I, topo II, topo III), prokaryotic topoisomerases (gyrase, topo IV) in E. Coli and S. Aureus, and recently we added DNA methyltransferase targets. We are also developing a solid phase assay for topo I (provisional patent filed). Please contact us for more information about how we can deliver expedited results with certainty to your research goals.